Nordex: Analyst Targets Diverge Sharply Even as Order Book Bulges
Published on 08/31/2026 at 17:11 | Editorial boerse-global.de
The gap between Wall Street's most bearish and most constructive views on Nordex has rarely been wider. RBC Capital Markets trimmed its price target on the German wind turbine maker to €36 from €38 on August 20, keeping an "Underperform" rating. Barclays, by contrast, more than doubled its target the very next day — lifting it to €35 from €15.80 — while maintaining a neutral "Equal Weight" stance. That the two targets now sit just €1 apart despite opposite ratings captures the peculiar moment Nordex finds itself in: operational momentum is hard to argue with, yet the valuation debate remains genuinely unsettled.
The shares were changing hands at €38.04 on Monday, down 1.2 percent on the session and roughly 6.7 percent below their 50-day moving average of €40.77. The recent pullback has been steady rather than sharp, but it stands in contrast to a year-to-date gain of 31 percent that has left the stock well ahead of where it started 2025.
A Quarter That Changed the Conversation
Barclays' dramatic re-rating did not happen in a vacuum. It followed Nordex's second-quarter results at the end of July, which showed EBITDA of €224 million — more than double the prior-year figure. The first-half EBITDA margin came in at 9.4 percent, while order intake in the project business accelerated to 3,054 megawatts in the second quarter, up 32.2 percent from 2,310 megawatts a year earlier.
Management also reaffirmed its 2026 guidance: revenue of €8.2 billion to €9.0 billion and an EBITDA margin between 8 and 11 percent. That combination of delivered results and a steady outlook appears to have underpinned Barclays' reassessment, even if the bank stopped short of turning bullish. RBC, for its part, acknowledged the solid numbers but chose to trim its target anyway — a reminder that the stock's run has left some analysts cautious about how much good news is already in the price.
The first-half picture reinforces the strength of the underlying trend. Order intake reached 4,923 megawatts in the first six months, up 9.6 percent year on year, with the second quarter clearly doing the heavy lifting. The average selling price rose to €0.95 million per megawatt from €0.92 million in the prior-year period — evidence that Nordex is regaining some pricing power. The order book stood at €17.0 billion as of June 30, against first-half revenue of €3.2 billion. The second-quarter EBITDA margin, meanwhile, came in above 10 percent.
New Contracts Across Two Continents
The commercial pipeline has stayed busy since those results landed. Early August brought three US orders totaling more than 480 megawatts, comprising 81 turbines of the N163/5.X model — a meaningful win in a market where the political environment for wind power remains uncertain. Around the same time, Nordex secured a 77-megawatt order in Romania, adding further geographic diversification to a year that has already seen a steady stream of contract announcements.
A subsequent order from the EFG Energy Farming group added 82 megawatts for citizen wind projects in Lower Saxony, specifically for the Erlte-Endel and Bad Essen sites. Yet the shares have shed roughly 4.5 percent since these contract wins became public — a sign that order news alone is no longer sufficient to move the needle.
Insider Buying Offers a Counterpoint
One signal that has historically carried weight with retail investors arrived about two weeks ago, when board member Ilya Hartmann purchased shares in two tranches of 2,806 each at prices of €40.97 and €40.98, for a combined outlay of nearly €230,000. Such purchases are often read as a statement of confidence from management, even if they do not alter the fundamental picture. Since those buys, the stock has drifted about 2.7 percent lower.
While investors weigh confidence signals in the markets, workplace safety demands its own form of diligence — and UK employers face serious consequences when risk documentation falls short. A free toolkit with 41 ready-to-use templates and checklists helps you document hazards properly and stay compliant. Download the free Risk Assessment Toolkit
Consolidation After a Strong Run
The stock closed Friday at €38.52, down 1.0 percent on the day. Over the past 30 days it has slipped 1.1 percent, though it remains up 32 percent year to date. From its 52-week high of €51.40, reached in late April, the shares currently sit about 25 percent lower.
The recent softness is notable precisely because the news flow has been constructive — new orders, insider buying, an upgraded price target. That the market has chosen to consolidate anyway suggests a significant portion of the good news was already priced in before it was officially announced. Meanwhile, Danish rival Vestas Wind Systems raised its full-year guidance in mid-August following strong quarterly results of its own, pointing to robust demand across the sector as a whole.
Just as Nordex's operational execution is being scrutinised, UK businesses face their own compliance scrutiny — and many are unknowingly exposed when it comes to workplace safety documentation. A free Health & Safety Toolkit provides risk assessments, checklists and toolbox talks covering key regulations like COSHH and PUWER, helping over 37,000 UK companies protect their employees and visitors. Get the free Health & Safety Toolkit
For now, Nordex investors are left weighing a simple tension: a company executing well operationally, with a growing order book and improving margins, against a stock that has already had a substantial run and now faces a wide spread of analyst opinion about what it is actually worth.
